Synlogic, Inc. (MIN.F)
- Previous Close
3.7500 - Open
-- - Bid --
- Ask --
- Day's Range
-- - 52 Week Range
3.3300 - 9.6000 - Volume
-- - Avg. Volume
0 - Market Cap (intraday)
0 - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-0.00 - EPS (TTM)
-11.5200 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
www.synlogictx.com6
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: MIN.F
Performance Overview: MIN.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MIN.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MIN.F
Valuation Measures
Market Cap
15.27M
Enterprise Value
1.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.25
Price/Book (mrq)
0.87
Enterprise Value/Revenue
1.51
Enterprise Value/EBITDA
-0.02
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.99%
Return on Equity (ttm)
-91.46%
Revenue (ttm)
3.37M
Net Income Avi to Common (ttm)
-57.28M
Diluted EPS (ttm)
-11.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
47.75M
Total Debt/Equity (mrq)
40.50%
Levered Free Cash Flow (ttm)
-22.27M
Company Insights: MIN.F
MIN.F does not have Company Insights